Health Trials

G12D Mutated KRAS

3

Review clinical trials related to G12D Mutated KRAS. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

Participants needed: 180
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Verastem, Inc.Updated: Jul 13, 2026Locations: 15
Eligibility criteria

Histopathology confirmed PDAC [+3]

Have any other documented co-existing common RAS mutation(s) [+10]

Read more
Status: Recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

Participants needed: 180
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Verastem, Inc.Updated: Jul 2, 2026Locations: 14
Eligibility criteria

Histopathology confirmed PDAC [+3]

Have any other documented co-existing common RAS mutation(s) [+10]

Read more
Status: Recruiting

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

Participants needed: 295
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Verastem, Inc.Updated: Apr 22, 2026Locations: 14
Eligibility criteria

Individuals ≥18 years of age. [+8]

Underwent major surgical procedure as defined by the Investigator, other than fo... [+7]

Read more